Altman Z-Score

Borealis Foods launched its high-protein Chef Woo noodles in Costco, a savvy move to tap the 'Ozempic Effect.' But can one product's promise save a company facing dire financial headwinds?

A Malaysian hotpot chain lands a massive data center deal, but with no tech experience and a plunging stock price, is this a brilliant pivot or a desperate gamble?

TKO's massive $800M share buyback signals supreme confidence, but a closer look at the financials reveals a complex story of growth, debt, and risk.

Ingles Markets' steady dividend is more than a financial report; it's a story of resilience, community commitment, and strategic fortitude after Hurricane Helene.

Triller's audacious acquisition of a SpaceX stake sends its stock soaring, but can this high-stakes bet on a space giant save a company plagued by financial woes?

The home-care provider just restructured over a billion in debt. While the company calls it an optimization, the data reveals a story of survival.

A silent productivity drain is costing businesses dearly. Over half the workforce aged 40-60 is managing elder care, and the financial and career toll is immense.

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.

While firms spend billions on tech, a new book argues the biggest data breaches stem from leadership gaps and process failures. Is your boardroom the real front line?

Soaring healthcare costs, fueled by GLP-1 drugs, have employers trapped. A new report shows why flexible benefits are becoming a critical survival strategy.

New research reveals Indigenous-led projects are not just a social good, but a critical economic engine for Canada's energy transition and resource economy.

As National Outlet Shopping Day returns, it's more than a sale. It's Simon's blueprint for the future of retail and a key test of consumer spending.

Canada's new 'AI for All' strategy bets billions on sovereign compute and closing its adoption gap. Can this ambitious plan build a uniquely Canadian AI future?

Facing dire financial warnings, Cosmos Health plans to sell its own facilities to fund a comeback. Is it a stroke of genius or a desperate final gambit?

Fairplay's new user verification signals a market-wide shift. As India's stringent new rules take hold, compliance is becoming a key strategic asset.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

Celebrating a half-century of progress, Liberty Hill Foundation's anniversary gala was an urgent plea to fund the fight for Los Angeles's future.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.